Title 69 RCW (new chapter); chapter 43.71C RCW
A manufacturer, or a third party acting for one, may not deny, restrict or prohibit a 340B drug reaching a covered entity, a contract pharmacy or an authorized location, and may not require data as a condition. Federally qualified health centers and certain hospitals report their 340B figures, the use of savings included, to the Health Care Authority by April 1 each year; manufacturers report 340B units and discounts.
- Bill
- E2SSB 5981
- Act
- Laws of 2026, ch. 227
- Session
- 2026
- In effect
- 11 June 2026
- Applies to
- Drug manufacturers and third parties that act for them; federally qualified health centers and hospitals that are 340B covered entities
- Limits
- The covered entity report applies to federally qualified health centers and to hospitals under 42 U.S.C. 256b(a)(4)(L) to (O). Their filing fees may cover no more than 25 percent of the authority's reporting costs.
- Enforcement
- In a covered entity's suit a court may award a civil penalty of up to $5,000 a day for each violation. The Attorney General may enforce under the consumer protection act. A late report can be fined $1,000 a day after 30 days to correct it.
A manufacturer or a third party acting on behalf of a manufacturer may not, directly or indirectly, deny, restrict, or prohibit the acquisition of a 340B drug by, or delivery of a 340B drug to, a covered entity